If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEMATOLOGY<br /> ISSN 2053-6631 Vol 6.1 • August 2018 • europeanmedical-journal.com<br /> INSIDE<br /> Review of<br /> EHA 2018<br /> Stockholm, Sweden<br /> Contents<br /> EDITORIAL BOARD 4<br /> WELCOME 7<br /> FOREWORD 9<br /> 01 CONGRESS REVIEW<br /> Review of EHA 2018, held in Stockholm, Sweden, 14th–17th June 2018 10<br /> 02 INTERVIEWS WITH EMJ HEMATOLOGY EDITORIAL BOARD<br /> Prof Smbat Dagbashyan 25<br /> Dr Ciaren Graham <a title="EMJ Hematology 6.1 2018 page 1" href="http://viewer.zmags.com/publication/8c5ca33c?page=1"> HEMATOLOGY ISSN 2053-6631 </a> <a title="EMJ Hematology 6.1 2018 page 2" href="http://viewer.zmags.com/publication/8c5ca33c?page=2"> Contents EDITORIAL BOARD </a> <a title="EMJ Hematology 6.1 2018 page 3" href="http://viewer.zmags.com/publication/8c5ca33c?page=3"> "We hope that you will enjoy the hand-picked </a> <a title="EMJ Hematology 6.1 2018 page 4" href="http://viewer.zmags.com/publication/8c5ca33c?page=4"> Editorial Board Editor-in-Chief Prof Emili Montse</a> <a title="EMJ Hematology 6.1 2018 page 5" href="http://viewer.zmags.com/publication/8c5ca33c?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Hematology 6.1 2018 page 6" href="http://viewer.zmags.com/publication/8c5ca33c?page=6"> EMJ Hematol. Chief Executive Officer Spencer Gore</a> <a title="EMJ Hematology 6.1 2018 page 7" href="http://viewer.zmags.com/publication/8c5ca33c?page=7"> Welcome A very warm welcome to you as we </a> <a title="EMJ Hematology 6.1 2018 page 8" href="http://viewer.zmags.com/publication/8c5ca33c?page=8"> Raise Your EXPECTATIONS This advert is int</a> <a title="EMJ Hematology 6.1 2018 page 9" href="http://viewer.zmags.com/publication/8c5ca33c?page=9"> Foreword Dear colleagues, It is a pleasure for me</a> <a title="EMJ Hematology 6.1 2018 page 10" href="http://viewer.zmags.com/publication/8c5ca33c?page=10"> </a> <a title="EMJ Hematology 6.1 2018 page 11" href="http://viewer.zmags.com/publication/8c5ca33c?page=11"> Congress Review Review of the 23rd Eu</a> <a title="EMJ Hematology 6.1 2018 page 12" href="http://viewer.zmags.com/publication/8c5ca33c?page=12"> impressive potential, must still be scrutinised t</a> <a title="EMJ Hematology 6.1 2018 page 13" href="http://viewer.zmags.com/publication/8c5ca33c?page=13"> New Hope for Epstein–Barr Virus-Associated Post-T</a> <a title="EMJ Hematology 6.1 2018 page 14" href="http://viewer.zmags.com/publication/8c5ca33c?page=14"> Ruxolitinib Associated with Better Outcomes for R</a> <a title="EMJ Hematology 6.1 2018 page 15" href="http://viewer.zmags.com/publication/8c5ca33c?page=15"> QuANTUM-R Study Results: A New Hope for Acute Mye</a> <a title="EMJ Hematology 6.1 2018 page 16" href="http://viewer.zmags.com/publication/8c5ca33c?page=16"> “In relapsed/refractory AML with FLT3-1TD mutatio</a> <a title="EMJ Hematology 6.1 2018 page 17" href="http://viewer.zmags.com/publication/8c5ca33c?page=17"> the skin, bleeding from the gums, nosebleeds, and</a> <a title="EMJ Hematology 6.1 2018 page 18" href="http://viewer.zmags.com/publication/8c5ca33c?page=18"> A Brief History of Immunotherapy Immunotherapy </a> <a title="EMJ Hematology 6.1 2018 page 19" href="http://viewer.zmags.com/publication/8c5ca33c?page=19"> 1960s–80s: Rapid Development and the Rise of Mono</a> <a title="EMJ Hematology 6.1 2018 page 20" href="http://viewer.zmags.com/publication/8c5ca33c?page=20"> 2010–Present: What Does the Future Hold? The mor</a> <a title="EMJ Hematology 6.1 2018 page 21" href="http://viewer.zmags.com/publication/8c5ca33c?page=21"> it was established that this disease is caused by</a> <a title="EMJ Hematology 6.1 2018 page 22" href="http://viewer.zmags.com/publication/8c5ca33c?page=22"> In the 1960s, doctors first used monthly blood tra</a> <a title="EMJ Hematology 6.1 2018 page 23" href="http://viewer.zmags.com/publication/8c5ca33c?page=23"> Jean Bernard Lifetime Achievement Award This year</a> <a title="EMJ Hematology 6.1 2018 page 24" href="http://viewer.zmags.com/publication/8c5ca33c?page=24"> </a> <a title="EMJ Hematology 6.1 2018 page 25" href="http://viewer.zmags.com/publication/8c5ca33c?page=25"> Interviews Our esteemed EMJ Hematology Editori</a> <a title="EMJ Hematology 6.1 2018 page 26" href="http://viewer.zmags.com/publication/8c5ca33c?page=26"> dissolution of the Union of Soviet Socialis</a> <a title="EMJ Hematology 6.1 2018 page 27" href="http://viewer.zmags.com/publication/8c5ca33c?page=27"> Improvements in haematology care have been achiev</a> <a title="EMJ Hematology 6.1 2018 page 28" href="http://viewer.zmags.com/publication/8c5ca33c?page=28"> In a recent abstract, you presented the report: O</a> <a title="EMJ Hematology 6.1 2018 page 29" href="http://viewer.zmags.com/publication/8c5ca33c?page=29"> tutorial was conducted in Yerevan. This huge scie</a> <a title="EMJ Hematology 6.1 2018 page 30" href="http://viewer.zmags.com/publication/8c5ca33c?page=30"> > Be active in the international arena by att</a> <a title="EMJ Hematology 6.1 2018 page 31" href="http://viewer.zmags.com/publication/8c5ca33c?page=31"> You have dedicated a significant amount of your pr</a> <a title="EMJ Hematology 6.1 2018 page 32" href="http://viewer.zmags.com/publication/8c5ca33c?page=32"> of their patients. They could also look at the pe</a> <a title="EMJ Hematology 6.1 2018 page 33" href="http://viewer.zmags.com/publication/8c5ca33c?page=33"> remind ourselves that the main objective of the E</a> <a title="EMJ Hematology 6.1 2018 page 34" href="http://viewer.zmags.com/publication/8c5ca33c?page=34"> even minimal residual disease-negative status is </a> <a title="EMJ Hematology 6.1 2018 page 35" href="http://viewer.zmags.com/publication/8c5ca33c?page=35"> Share your knowledge with the w</a> <a title="EMJ Hematology 6.1 2018 page 36" href="http://viewer.zmags.com/publication/8c5ca33c?page=36"> Planning Your Next Move in Philadelphia Chro</a> <a title="EMJ Hematology 6.1 2018 page 37" href="http://viewer.zmags.com/publication/8c5ca33c?page=37"> In the second presentation, Dr Bassan and Prof Dr</a> <a title="EMJ Hematology 6.1 2018 page 38" href="http://viewer.zmags.com/publication/8c5ca33c?page=38"> Adult ALL (EWALL) and the European Study Group-MR</a> <a title="EMJ Hematology 6.1 2018 page 39" href="http://viewer.zmags.com/publication/8c5ca33c?page=39"> In Ph+ ALL, the complexity of mutant subclones ha</a> <a title="EMJ Hematology 6.1 2018 page 40" href="http://viewer.zmags.com/publication/8c5ca33c?page=40"> Occurrences of HSCT 7,000 6,000 5,000 4,000 </a> <a title="EMJ Hematology 6.1 2018 page 41" href="http://viewer.zmags.com/publication/8c5ca33c?page=41"> TKI can be used to prevent relapse after a</a> <a title="EMJ Hematology 6.1 2018 page 42" href="http://viewer.zmags.com/publication/8c5ca33c?page=42"> References 1. Baccarani M, Soverini S. Molec</a> <a title="EMJ Hematology 6.1 2018 page 43" href="http://viewer.zmags.com/publication/8c5ca33c?page=43"> ECOG2993: Addition of imatinib to a standard trea</a> <a title="EMJ Hematology 6.1 2018 page 44" href="http://viewer.zmags.com/publication/8c5ca33c?page=44"> Abstract Reviews Take a look at these abstract </a> <a title="EMJ Hematology 6.1 2018 page 45" href="http://viewer.zmags.com/publication/8c5ca33c?page=45"> Table 1: Characteristics of patients. Clinical ch</a> <a title="EMJ Hematology 6.1 2018 page 46" href="http://viewer.zmags.com/publication/8c5ca33c?page=46"> a median age of 50 years were enrolled in the stu</a> <a title="EMJ Hematology 6.1 2018 page 47" href="http://viewer.zmags.com/publication/8c5ca33c?page=47"> Mutations of c-MPL can either result </a> <a title="EMJ Hematology 6.1 2018 page 48" href="http://viewer.zmags.com/publication/8c5ca33c?page=48"> 8. Ballmaier M et al. Flow cytometric detectio</a> <a title="EMJ Hematology 6.1 2018 page 49" href="http://viewer.zmags.com/publication/8c5ca33c?page=49"> However, no significant changes in CD62P or </a> <a title="EMJ Hematology 6.1 2018 page 50" href="http://viewer.zmags.com/publication/8c5ca33c?page=50"> lenalidomide in patients with relapsed and/or ref</a> <a title="EMJ Hematology 6.1 2018 page 51" href="http://viewer.zmags.com/publication/8c5ca33c?page=51"> 6. Dipartimento di Ingegneria Chimica, dei Mater</a> <a title="EMJ Hematology 6.1 2018 page 52" href="http://viewer.zmags.com/publication/8c5ca33c?page=52"> congenital dyserythropoietic anemias. Expert Rev </a> <a title="EMJ Hematology 6.1 2018 page 53" href="http://viewer.zmags.com/publication/8c5ca33c?page=53"> inhibitors (TKI), which have dramatically improve</a> <a title="EMJ Hematology 6.1 2018 page 54" href="http://viewer.zmags.com/publication/8c5ca33c?page=54"> GEP detected 264 statistically significant</a> <a title="EMJ Hematology 6.1 2018 page 55" href="http://viewer.zmags.com/publication/8c5ca33c?page=55"> myeloid leukaemia (AML).2 It has been shown that,</a> <a title="EMJ Hematology 6.1 2018 page 56" href="http://viewer.zmags.com/publication/8c5ca33c?page=56"> Patients with a high CD34+/CD38- cell burden had </a> <a title="EMJ Hematology 6.1 2018 page 57" href="http://viewer.zmags.com/publication/8c5ca33c?page=57"> from the Thalassaemia International Federation (T</a> <a title="EMJ Hematology 6.1 2018 page 58" href="http://viewer.zmags.com/publication/8c5ca33c?page=58"> Biomarkers are essential tools for tailoring</a> <a title="EMJ Hematology 6.1 2018 page 59" href="http://viewer.zmags.com/publication/8c5ca33c?page=59"> sedoanalgesia could influence the quality of the b</a> <a title="EMJ Hematology 6.1 2018 page 60" href="http://viewer.zmags.com/publication/8c5ca33c?page=60"> References 1. Cerchione C et al. Combined or</a> <a title="EMJ Hematology 6.1 2018 page 61" href="http://viewer.zmags.com/publication/8c5ca33c?page=61"> Table 1: Novel agents for management of relapsed </a> <a title="EMJ Hematology 6.1 2018 page 62" href="http://viewer.zmags.com/publication/8c5ca33c?page=62"> + give me peace of mind with fast Chronic Mye</a> <a title="EMJ Hematology 6.1 2018 page 63" href="http://viewer.zmags.com/publication/8c5ca33c?page=63"> Allogeneic Haematopoietic Stem Cell Tran</a> <a title="EMJ Hematology 6.1 2018 page 64" href="http://viewer.zmags.com/publication/8c5ca33c?page=64"> phase of CML and those with multiple TKI treatmen</a> <a title="EMJ Hematology 6.1 2018 page 65" href="http://viewer.zmags.com/publication/8c5ca33c?page=65"> Worldwide Network for Blood and Marrow Trans</a> <a title="EMJ Hematology 6.1 2018 page 66" href="http://viewer.zmags.com/publication/8c5ca33c?page=66"> especially for those in low-income countries.31 I</a> <a title="EMJ Hematology 6.1 2018 page 67" href="http://viewer.zmags.com/publication/8c5ca33c?page=67"> imatinib for the prevention of disease relapse fo</a> <a title="EMJ Hematology 6.1 2018 page 68" href="http://viewer.zmags.com/publication/8c5ca33c?page=68"> and in restoring complete donor chimerism,63,64 a</a> <a title="EMJ Hematology 6.1 2018 page 69" href="http://viewer.zmags.com/publication/8c5ca33c?page=69"> 9. Gratwohl A et al. Risk assessment </a> <a title="EMJ Hematology 6.1 2018 page 70" href="http://viewer.zmags.com/publication/8c5ca33c?page=70"> 2017;52(6):811-7. 44. Or R et al. Nonmyeloablati</a> <a title="EMJ Hematology 6.1 2018 page 71" href="http://viewer.zmags.com/publication/8c5ca33c?page=71"> Therapeutic Options in Myelodysplastic Syndromes:</a> <a title="EMJ Hematology 6.1 2018 page 72" href="http://viewer.zmags.com/publication/8c5ca33c?page=72"> updated scoring system, the IPSS-R, is available </a> <a title="EMJ Hematology 6.1 2018 page 73" href="http://viewer.zmags.com/publication/8c5ca33c?page=73"> Table 2: Revised international prognostic scoring</a> <a title="EMJ Hematology 6.1 2018 page 74" href="http://viewer.zmags.com/publication/8c5ca33c?page=74"> Table 3: Established and emerging therapies for m</a> <a title="EMJ Hematology 6.1 2018 page 75" href="http://viewer.zmags.com/publication/8c5ca33c?page=75"> Standard AML-based chemotherapy (classically, an </a> <a title="EMJ Hematology 6.1 2018 page 76" href="http://viewer.zmags.com/publication/8c5ca33c?page=76"> patients with relapsed or refractory MDS or AML t</a> <a title="EMJ Hematology 6.1 2018 page 77" href="http://viewer.zmags.com/publication/8c5ca33c?page=77"> in high-risk MDS and AML patients wit</a> <a title="EMJ Hematology 6.1 2018 page 78" href="http://viewer.zmags.com/publication/8c5ca33c?page=78"> OTHER NOVEL THERAPEUTICS Immune Checkpoint Inhibi</a> <a title="EMJ Hematology 6.1 2018 page 79" href="http://viewer.zmags.com/publication/8c5ca33c?page=79"> molar ratio, was recently U.S. Food and Drug Admi</a> <a title="EMJ Hematology 6.1 2018 page 80" href="http://viewer.zmags.com/publication/8c5ca33c?page=80"> 22. Harel S et al. Outcome of patients </a> <a title="EMJ Hematology 6.1 2018 page 81" href="http://viewer.zmags.com/publication/8c5ca33c?page=81"> myelodysplastic syndromes with prior hypomethylat</a> <a title="EMJ Hematology 6.1 2018 page 82" href="http://viewer.zmags.com/publication/8c5ca33c?page=82"> Making Rituximab Directly Cytotoxic for Substanti</a> <a title="EMJ Hematology 6.1 2018 page 83" href="http://viewer.zmags.com/publication/8c5ca33c?page=83"> approval in 1997, RTX has been routinely used for</a> <a title="EMJ Hematology 6.1 2018 page 84" href="http://viewer.zmags.com/publication/8c5ca33c?page=84"> Antibody-Dependent Cellular Cytotoxicity RTX can </a> <a title="EMJ Hematology 6.1 2018 page 85" href="http://viewer.zmags.com/publication/8c5ca33c?page=85"> The Adverse Impact of Chemotherapy on Rituximab A</a> <a title="EMJ Hematology 6.1 2018 page 86" href="http://viewer.zmags.com/publication/8c5ca33c?page=86"> chemotherapy might compromise OBZ- me</a> <a title="EMJ Hematology 6.1 2018 page 87" href="http://viewer.zmags.com/publication/8c5ca33c?page=87"> complex demonstrated substantially enhanced CD20-</a> <a title="EMJ Hematology 6.1 2018 page 88" href="http://viewer.zmags.com/publication/8c5ca33c?page=88"> and liver.7 The mice were treated intravenously e</a> <a title="EMJ Hematology 6.1 2018 page 89" href="http://viewer.zmags.com/publication/8c5ca33c?page=89"> correlates with prolonged response following ritu</a> <a title="EMJ Hematology 6.1 2018 page 90" href="http://viewer.zmags.com/publication/8c5ca33c?page=90"> with relapsed CD20+ B-cell non- Hodgkin's lymphom</a> <a title="EMJ Hematology 6.1 2018 page 91" href="http://viewer.zmags.com/publication/8c5ca33c?page=91"> Interact with us on social media. </a> <a title="EMJ Hematology 6.1 2018 page 92" href="http://viewer.zmags.com/publication/8c5ca33c?page=92"> Staging of Mycosis Fungoides and Sézary </a> <a title="EMJ Hematology 6.1 2018 page 93" href="http://viewer.zmags.com/publication/8c5ca33c?page=93"> INTRODUCTION Mycosis fungoides (MF) is the most c</a> <a title="EMJ Hematology 6.1 2018 page 94" href="http://viewer.zmags.com/publication/8c5ca33c?page=94"> The early and advanced stages of MF are IA–IIA an</a> <a title="EMJ Hematology 6.1 2018 page 95" href="http://viewer.zmags.com/publication/8c5ca33c?page=95"> while maintaining the ability to simultaneously t</a> <a title="EMJ Hematology 6.1 2018 page 96" href="http://viewer.zmags.com/publication/8c5ca33c?page=96"> splenomegaly is rare in healthy persons and a spl</a> <a title="EMJ Hematology 6.1 2018 page 97" href="http://viewer.zmags.com/publication/8c5ca33c?page=97"> skin-directed therapy. Most of these patient</a> <a title="EMJ Hematology 6.1 2018 page 98" href="http://viewer.zmags.com/publication/8c5ca33c?page=98"> peripheral blood smears;3 however, due to the exp</a> <a title="EMJ Hematology 6.1 2018 page 99" href="http://viewer.zmags.com/publication/8c5ca33c?page=99"> and suggesting that patients presenti</a> <a title="EMJ Hematology 6.1 2018 page 100" href="http://viewer.zmags.com/publication/8c5ca33c?page=100"> fungoides & Sezary Syndrome. J Invest Dermatol. 2</a> <a title="EMJ Hematology 6.1 2018 page 101" href="http://viewer.zmags.com/publication/8c5ca33c?page=101"> Iron Deficiency Anaemia in Pregnancy: Developed V</a> <a title="EMJ Hematology 6.1 2018 page 102" href="http://viewer.zmags.com/publication/8c5ca33c?page=102"> in pregnancy according to grades of severity to </a> <a title="EMJ Hematology 6.1 2018 page 103" href="http://viewer.zmags.com/publication/8c5ca33c?page=103"> The situation is no different in other Asi</a> <a title="EMJ Hematology 6.1 2018 page 104" href="http://viewer.zmags.com/publication/8c5ca33c?page=104"> as the first step used in primary care practice. T</a> <a title="EMJ Hematology 6.1 2018 page 105" href="http://viewer.zmags.com/publication/8c5ca33c?page=105"> its use to the most complicated cases, in which t</a> <a title="EMJ Hematology 6.1 2018 page 106" href="http://viewer.zmags.com/publication/8c5ca33c?page=106"> Table 1: Elemental iron content and dose per tabl</a> <a title="EMJ Hematology 6.1 2018 page 107" href="http://viewer.zmags.com/publication/8c5ca33c?page=107"> Absorption of oral iron can be increased by takin</a> <a title="EMJ Hematology 6.1 2018 page 108" href="http://viewer.zmags.com/publication/8c5ca33c?page=108"> Among intramuscular preparations, the only on</a> <a title="EMJ Hematology 6.1 2018 page 109" href="http://viewer.zmags.com/publication/8c5ca33c?page=109"> A multi-centre study. Eur J Obstet Gynecol Reprod</a> <a title="EMJ Hematology 6.1 2018 page 110" href="http://viewer.zmags.com/publication/8c5ca33c?page=110"> Coming soon. </a> <a title="EMJ Hematology 6.1 2018 page 111" href="http://viewer.zmags.com/publication/8c5ca33c?page=111"> Buyer's Guide > ABBVIE > ABLYNX NV > ADAPTIVE BIO</a> <a title="EMJ Hematology 6.1 2018 page 112" href="http://viewer.zmags.com/publication/8c5ca33c?page=112"> Never miss an update again. J</a>